The Tecentriq/Avastin Combo: Roche Details Renal Cell Cancer Benefits
Roche has continued to drip-feed results from the IMmotion151 Phase III study, this time describing the magnitude of the beneficial responses observed with the first-line use of the Tecentriq-Avastin combination in patients with advanced renal cell cancer.
You may also be interested in...
Study of PD-L1/TKI combo succeeded in an all comers population across risk groups, which could be differentiating, for a while.
Rather than buying its way out of trouble, Roche is backing its new products, notably the multiple sclerosis drug Ocrevus, the PD-L1 inhibitor Tecentriq and the lung cancer treatment Alecensa to offset the battering from biosimilar competition to some of its big-selling cancer therapies.
In a video interview at the Biotech Showcase, Exelixis CEO Michael Morrissey discusses the recent launch of cabozantinib in first-line renal cell carcinoma and looks ahead to filing soon in liver cancer.